Caffeine & adenosine receptors in Alzheimer's Disease
Emilie Faivre, Bryan Thiroux, Kévin Carvalho, Claire Montmasson, Agathe Launay, Thibaud Lebouvier
We are interested in delineating the neuroglial contribution of adenosine A2A receptors, the target of caffeine, to the development of cognitive deficits in Alzheimer's disease.
In parallel, we are developing
a double-blinded phase III clinical trial
testing the effect of caffeine
in early and moderate
Alzheimer's Disease patients.